JPH0258245B2 - - Google Patents

Info

Publication number
JPH0258245B2
JPH0258245B2 JP59173537A JP17353784A JPH0258245B2 JP H0258245 B2 JPH0258245 B2 JP H0258245B2 JP 59173537 A JP59173537 A JP 59173537A JP 17353784 A JP17353784 A JP 17353784A JP H0258245 B2 JPH0258245 B2 JP H0258245B2
Authority
JP
Japan
Prior art keywords
acid amide
water
added
solubilization
stabilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP59173537A
Other languages
Japanese (ja)
Other versions
JPS6150918A (en
Inventor
Makoto Tsuboi
Yutaka Ando
Kenji Matsui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichimaru Pharcos Co Ltd
Original Assignee
Ichimaru Pharcos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichimaru Pharcos Co Ltd filed Critical Ichimaru Pharcos Co Ltd
Priority to JP59173537A priority Critical patent/JPS6150918A/en
Publication of JPS6150918A publication Critical patent/JPS6150918A/en
Publication of JPH0258245B2 publication Critical patent/JPH0258245B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant

Description

【発明の詳細な説明】[Detailed description of the invention]

〔イ〕 発明の目的 本発明は、バイカリン(以下、便宜上、これを
単にBa・Gと記す。)又は、バイカレイン(以
下、便宜上、これを単にBaと記す。)を可溶化し
た、安定な化粧料用組成物に関する。 〔産業上の利用分野〕 本発明による組成物は、抗アレルギー作用又は
抗ヒスタミン作用が知られる、Ba・G、又は、
Baを安定に含有し、軟膏類や絆創膏類をはじめ
とする皮膚外用剤や、化粧水、ヘアトニツクとは
じめとする、肌用、頭髪用などの皮膚化粧料(以
下、便宜上、両製剤を単に外用剤と述べる)など
へ応用することができる。 〔従来の技術〕 Ba・G又はBaは、以下に示す構造を有し、水
には不溶性の物質として知られる。Ba・GやBa
は、共に、アルカリ溶液(PH8.6付近)中では溶
解する。又、熱酢酸中にも溶解する。この他、エ
タノール、メタノールには、ごく微量に溶解する
も、例えば、Ba・Gでは、エタノール中に0.01
%、エタノール中では、その約半量、アセトンで
は、メタノールに溶解する量の半量程度が溶け
る。 その溶解・安定性(可溶量)についてみれば、
次表(表−1)に示す如くであつた。
[B] Purpose of the Invention The present invention provides a stable cosmetic product in which baicalin (hereinafter, for convenience, this is simply referred to as Ba.G) or baicalein (hereinafter, for convenience, this is simply referred to as Ba) is solubilized. The present invention relates to a food composition. [Industrial Application Field] The composition according to the present invention contains Ba, G, or
Stably contains Ba, and is used in external skin preparations such as ointments and bandages, as well as skin and hair cosmetics such as lotions and hair tonics (hereinafter, for convenience, both preparations are simply used externally). It can be applied to such things as agents (described as agents). [Prior Art] Ba.G or Ba has the structure shown below and is known as a substance that is insoluble in water. Ba・G or Ba
Both dissolve in alkaline solution (pH around 8.6). It also dissolves in hot acetic acid. In addition, ethanol and methanol dissolve in very small amounts, but for example, Ba・G dissolves in ethanol at 0.01
%, in ethanol, about half the amount dissolves, and in acetone, about half the amount that dissolves in methanol. Regarding its solubility and stability (soluble amount),
The results were as shown in the following table (Table 1).

〔発明が解決しようとする問題点〕[Problem that the invention seeks to solve]

黄〓やそのエキス、あるいはBa・G又はBaを
外用剤を始め、内服用剤に用いるに当たつて、江
田らの1966年における、抗ヒスタミン作用、抗ア
セチルコリン作用が注目され、その製剤化研究が
活発に行なわれている。 しかしながら、始めにも触れた如く、Ba・G
やBaは、水に不溶であること。エタノールにも
ほとんど溶解しないことが、欠点となり、その結
果として、水やエタノールを処方中に用いること
の多い、澄明状の液体製品中に用いるとなれば、
配合後に発生するBa・GやBaの沈殿を引き起
し、充分な効果を発揮するには至らないことが多
かつた。 従つて、Ba・GやBaの沈殿防止策としては、
界面活性剤などを用い、例えば、軟膏類、クリー
ム、乳液、ミルクローシヨンタイプの分散又は乳
化状態での製剤化手段が必要であつた。 しかし、乳化又は分散状態では、溶解された状
態と異なり、期待される効果は半減し、充分な作
用を発揮しないし、用いた界面活性剤などは、目
的とする虚弱体質者や、特に、肌のカブレやすい
体質者におけるじんま疹や湿疹に対し、逆に増悪
するなどの欠点がある。 その為、Ba・GやBaを製剤化するに当つて
は、必須条件の一つとして、出来る限り、界面活
性剤などを用いないで製剤化を行なうこと。 又、治療用としての製剤中には、Ba・G又は
Baが0.05%以上、更に望ましくは、0.1%以上を
含有した、安定な水溶液となす必要があつた。 Ba・GやBaは、安定な水溶化状態にあるとき
は、外用剤中の含有量としては、0.01%でも、あ
る程度、長期連用塗布を行うと、肌のカブレやじ
んま疹、カユミなどを防ぐ効果が得られるように
なる。 しかし、分散剤を用いて製剤化するときでは、
Ba・GやBaは、大量に配合することは可能であ
つても、残念ながら、その効果は充分に発揮され
ないし、無駄な用い方としていることになる。 つまり、Ba・GやBaが抗ヒスタミン作用を有
するからと言つて、これを単に分散や乳化によつ
て配合しても、溶解した状態にないときは、充分
な効果が得られなくなることである。 一方、Ba・GやBaは、始めにも述べた如く、
公知な可溶化法としては、アルカリ溶液を用いれ
ば、良く溶けるも、外用剤や飲料などの経口投与
においては、共に中性又は酸性側で用いることが
望ましいとされる。特にアレルギー体質者向の外
用剤では、アルカリ溶解液は、これによつて、逆
に炎症や湿疹及び皮膚疾患を増悪させることが多
く、不適当である。 以上の欠点をふまえ、本発明者らは、Ba・G、
Baの有利な製剤化法の確立の為の研究を開始し
た。 〔ロ〕 発明の構成 〔問題点を解決するための手段〕 本発明者らは、Ba・G、Baの有する治療的効
果に期待し、外用剤として用いる際の最善の方法
について、実験を続けた結果、次の実施例で示す
如くの溶解液を製することに成功した。 すなわち、Ba・G又はBaを0.1〜0.6%含有し、
可溶化安定剤として、アミノ酸と糖を併用する
か、又は酸アミド化合物か尿素を用いることによ
つて、その液中でBa・G又はBaは、長期にわた
り、安定に溶解しているわけである。 実施例 1 黄〓から単離されたBa・G又はBa(一丸フア
ルコス製)を入手して、あらかじめ、次に示す(A)
〜(C)の混液を調製しておき、そのいずれかの混液
中に、Ba・G又はBaを0.1〜0.6%加える。添加
は60〜80℃の加温下で、ゆるやかに撹拌しながら
行う。しかし、加温下では今だ完全に溶解せず、
更に、冷却することによつて可溶部のBa・G又
はBaは沈殿する。 <混液> (A) 水とプロピレングルコールの割合が1:1の
混液 (B) 水とブチレングルコールの割合が1:1の混
液 (C) 水とエタノールの割合が1:1の溶液 上記の混液中に、Ba・G又はBaを加えた後、
次に示す、可溶化安定剤として、少なくともプロ
リン1種類からなるアミノ酸類(D)を用い、そのア
ミノ酸の総添加量としては、Ba・G又はBaの溶
液中の含有量に対して、同量又は2倍量を加え
る。(D)を加えた後、更に、少なくともサツカロー
ス1種類からなる糖類(E)を用い、その糖類の総添
加量がBa・G又はBaの混液中の含有量に対し
て、同量又は2倍量を加える。この(D)と(E)を添加
する際は、60〜80℃の加温下で、Ba・G又はBa
を添加した後、引き続き行えば良いが、(D)と(E)の
添加順序は、逆に(E)を先に、(D)を行つても良い。 一方、(D)と(E)を用いない時は、(F)の酸アミド化
合物などの類の中から、その1種を混液中の
Ba・G又はBaの含有量に対して、同量又は2倍
量までを、60〜80℃の加温下で加える。 <可溶化安定剤> (D) アミノ酸類 プロリンを必須成分とし、アルギニン、アス
パラギン酸、セリン、グリシン、アラニン、バ
リン、メチオニン、チロシン、リジン、ヒスチ
ジン、グルタミン酸、イソロイシン、ロイシ
ン、フエニルアラニン、スレオニン、システイ
ン、シスチン、トリプトフアン、ハイドロキシ
プロリン、オルニチン。 (E) 糖類 サツカロースを必須成分とし、グルコース、
フルクトース、キシロース、ガラクトース、マ
ンノース。 (F) 酸アミド化合物などの類 ニコチン酸アミド、チオクト酸アミド、グル
クロン酸アミド、尿素。 つまり、ここで用いる可溶化安定剤は、アミノ
酸類と糖類を、Ba・G又はBaの含有量に対し
て、同量か2倍量の範囲で用いる、アミノ酸と糖
類との併用によるか、これに替えて、酸アミド化
合物の中から1種類の単独、又は尿素の単独の使
用によるものである。 上述した操作方法によつて、最終的に得られた
Ba・G又はBa含有組成液は、共に長期間にわた
り安定である。 尚、上述の可溶化安定化剤として、アミノ酸類
(D)のみの使用や、糖類(E)のみの使用では、Ba・
G又はBaの安定な溶解量は、0.1〜0.3付近であ
る。 又、(D)と(E)を併用した後に、更に(F)から選択さ
れたいずれかの成分を加えると、その溶解量とし
ては、上限が1%弱となる。しかし、この場合、
マイナス20℃の低温下に長期保存後の経時的変化
に付いてみると、多少の沈殿物が認められるも、
常温に戻すと、沈殿物は再び溶解する。 〔ハ〕 発明の効果 本発明による上記の実施例において得られた、
Ba・G又はBa含有組成液は、次表(表−2)、
及び(表−3)で示すごとく、常温下はもとよ
り、加熱処理、45℃恒温槽、マイナス20℃冷凍下
の条件下で、長時間又は長期間にわたり、沈殿物
の発生は認められない。 さらに、このBa・G又はBa含有組成液は、黄
褐色の透明な液体として得られるため、そのま
ま、外用剤として用いることができる他、これを
既知の化粧水、ヘアートニツクを始め、肌用、頭
髪用の透明状の液体製品の処方中に用いることが
できる。その際の添加量としては、1〜10%程度
配合して用いればよい。もちろん、軟膏類や絆創
膏類を始め、クリームや乳液、ローシヨン、その
他、リツプクリーム、粉末タイプの外用剤中にも
添加できる。 又、実施例で示した混液が(C)であり、可溶化安
定剤が(F)の尿素以外で用いて得られた、Ba・G
又はBa含有組成液であれば、経口投与すること
もでき、例えば、ドリンク剤、シロツプ形態の小
児向内服剤中にも配合できる。 Ba・GがBaを含有する本発明による組成液
は、アレルギー性の諸疾患に対して、その症状を
軽減させる効果があると共に、虚弱体質者の改善
を目的となし、例えば、じんま疹又は刺激を緩和
するのに役立つ。又、アレルギー性の皮膚疾患を
伴う、荒れやすい肌に対しては、実施例で得られ
たBa・G又はBaを含有する組成液を局所に塗布
し、局部が乾いたところで、卵黄油又は卵黄レシ
チン分として25〜60%前後のワセリン又はペース
ト状物の塗布と併用させる方法で、長期間の連用
を続けるとアレルギー体質が改善される。 これは両者を服用しても同様の効果が期待でき
る。特に、この効果は、小児において、著明であ
り、健康飲料又は健康食品向の体質改善を目的と
する、素材としても、Ba・GやBa含有組成液
は、卵黄レシチンと共に併用することも可能であ
る。(表−4)は治験成績を示したものである。 一方、始めの頃で示したところの公開特許公
報、昭59−73509号によれば、黄〓の粉末や抽出
エキス(粗製バイカリンと推定される)が、肌荒
れ、シミ、ソバカス、ニキビ、カユミに効果があ
ると報告されている。 そこで、実施例で得られたBa・G又はBaを含
有する組成液を用いて、外用塗布について治験を
試みた結果、シミ、ソバカスに対しては、約3か
月間の連用(1日2〜3回塗布)してみたが、あ
まり期待する効果は得られなかつた。 一方、カユミに対しては、既知の抗ヒスタミン
含有軟膏と比較しても、ほぼ同様の効果が得られ
有効である。又、蚊にさされた局所には、速効性
を有し、カユミを消滅させる。湿疹では、慢性型
の湿疹には有効であるが、副腎皮膚ホルモン含有
軟膏が示すような、速効性は期待できなかつた。 更に、ニキビに対しては、紅潮を伴う初期の膨
張に対しては、その膨張を消失する消炎傾向が示
された。但し、全般的にみて、上述した効果を高
めるには、Ba・G又はBaを含有組成液の単独塗
布よりも、外用剤として用いる際には、いずれの
場合でも少量のメントールを加えた時の方が優れ
ている。
In 1966, Eda et al.'s antihistamine and antiacetylcholine effects attracted attention when using Huang, its extract, or Ba/G or Ba for internal and external preparations, and research on its formulation was conducted. is being actively carried out. However, as mentioned at the beginning, Ba・G
and Ba must be insoluble in water. A drawback is that it is poorly soluble in ethanol, and as a result, when used in clear liquid products, where water or ethanol are often used in the formulation.
This often leads to precipitation of Ba, G, and Ba that occurs after blending, and it is often not possible to achieve a sufficient effect. Therefore, as a measure to prevent precipitation of Ba/G and Ba,
It is necessary to formulate formulations in the form of ointments, creams, emulsions, and milk lotions in the form of dispersions or emulsions using surfactants and the like. However, in an emulsified or dispersed state, unlike in a dissolved state, the expected effect is halved, and sufficient action is not exerted. It has disadvantages such as worsening hives and eczema in people who are prone to rashes. Therefore, when formulating Ba/G or Ba, one of the essential conditions is to do the formulation without using surfactants as much as possible. In addition, Ba, G or
It was necessary to create a stable aqueous solution containing 0.05% or more Ba, more preferably 0.1% or more. When Ba/G and Ba are in a stable water-soluble state, even if the content in external preparations is 0.01%, long-term application can prevent skin irritation, hives, itching, etc. effect will be obtained. However, when formulating using a dispersant,
Although Ba/G and Ba can be blended in large amounts, unfortunately, their effects are not sufficiently exhibited and their use is wasted. In other words, even though Ba/G and Ba have antihistamine effects, even if they are simply blended by dispersion or emulsification, if they are not in a dissolved state, sufficient effects will not be obtained. . On the other hand, Ba・G and Ba, as mentioned at the beginning,
As a known solubilization method, if an alkaline solution is used, it dissolves well, but for oral administration of external preparations and drinks, it is preferable to use both neutral or acidic solutions. Particularly in external preparations for people with allergies, alkaline solutions are inappropriate because they often worsen inflammation, eczema, and skin diseases. Based on the above drawbacks, the present inventors have developed Ba・G,
Research has begun to establish an advantageous formulation method for Ba. [B] Structure of the Invention [Means for Solving the Problems] The present inventors have high hopes for the therapeutic effects of Ba, G, and Ba, and have continued to experiment with the best way to use them as external preparations. As a result, we succeeded in producing a solution as shown in the following example. That is, it contains 0.1 to 0.6% Ba/G or Ba,
By using an amino acid and sugar together, or using an acid amide compound or urea as a solubilization stabilizer, Ba, G or Ba can be stably dissolved in the solution for a long period of time. . Example 1 Ba.
A mixture of (C) is prepared in advance, and 0.1 to 0.6% of Ba.G or Ba is added to either of the mixtures. The addition is carried out at a temperature of 60 to 80°C with gentle stirring. However, it still does not dissolve completely under heating.
Further, by cooling, Ba, G or Ba in the soluble portion precipitates. <Mixture> (A) Mixture of water and propylene glycol in a ratio of 1:1 (B) Mixture of water and butylene glycol in a ratio of 1:1 (C) Solution of water and ethanol in a ratio of 1:1 Above After adding Ba・G or Ba to the mixed solution,
As the solubilization stabilizer shown below, the amino acids (D) consisting of at least one type of proline are used, and the total amount of the amino acids added is the same as the content in the solution of Ba, G or Ba. Or add double the amount. After adding (D), use a saccharide (E) consisting of at least one type of sutucarose so that the total amount of the saccharide added is the same or twice the content in the mixture of Ba and G or Ba. Add quantity. When adding these (D) and (E), Ba・G or Ba
It may be continued after adding (D) and (E), but the order of addition of (D) and (E) may be reversed, with (E) being added first and then (D) being added. On the other hand, when (D) and (E) are not used, one of the acid amide compounds of (F) is added to the mixture.
Add the same amount or up to twice the amount of Ba.G or Ba content under heating at 60 to 80°C. <Solubilization stabilizer> (D) Amino acids Proline is an essential component, arginine, aspartic acid, serine, glycine, alanine, valine, methionine, tyrosine, lysine, histidine, glutamic acid, isoleucine, leucine, phenylalanine, threonine, Cysteine, cystine, tryptophan, hydroxyproline, ornithine. (E) Saccharide Satucarose is an essential component, glucose,
fructose, xylose, galactose, mannose. (F) Acid amide compounds, etc. Nicotinic acid amide, thioctic acid amide, glucuronic acid amide, urea. In other words, the solubilizing stabilizer used here may be the same or twice the amount of amino acids and saccharides relative to the content of Ba, G, or Ba, or a combination of amino acids and saccharides; Instead, one type of acid amide compound or urea may be used alone. The final result obtained by the above-mentioned operation method is
Both Ba.G and Ba-containing composition liquids are stable over a long period of time. In addition, as the above-mentioned solubilization stabilizer, amino acids
When using only (D) or only saccharide (E), Ba・
The stable dissolution amount of G or Ba is around 0.1 to 0.3. Further, if any component selected from (F) is further added after using (D) and (E) together, the upper limit of the amount dissolved will be a little less than 1%. But in this case,
Looking at the changes over time after long-term storage at a low temperature of -20℃, some precipitates were observed,
When the temperature returns to room temperature, the precipitate dissolves again. [C] Effects of the invention Obtained in the above embodiments according to the present invention,
Ba・G or Ba-containing composition liquid is shown in the following table (Table-2).
As shown in Table 3, no precipitation was observed not only at room temperature but also under conditions of heat treatment, 45°C constant temperature bath, and -20°C freezing for long periods of time. Furthermore, since this Ba/G or Ba-containing liquid composition is obtained as a yellow-brown transparent liquid, it can be used as an external preparation as it is, and it can also be used in known lotions, hair tonics, skin care products, hair care products, etc. It can be used in the formulation of clear liquid products for use. In this case, the amount to be added may be about 1 to 10%. Of course, it can also be added to ointments, bandages, creams, milky lotions, lotions, lip creams, and powder-type external preparations. In addition, the mixture shown in the example is (C), and the solubilization stabilizer is Ba・G obtained by using other than urea (F).
Or, if it is a Ba-containing composition liquid, it can be administered orally, and it can also be incorporated into, for example, a drink or a syrup form of an oral preparation for children. The composition liquid according to the present invention in which Ba/G contains Ba has the effect of alleviating the symptoms of various allergic diseases, and is aimed at improving people with weak constitutions, such as hives or Helps relieve irritation. In addition, for skin prone to roughness accompanied by allergic skin diseases, apply the Ba/G or Ba-containing composition solution obtained in the example locally, and when the local area dries, apply egg yolk oil or egg yolk. This method is used in conjunction with the application of Vaseline or a paste with a lecithin content of around 25-60%, and continued use over a long period of time will improve allergic tendencies. Similar effects can be expected even if both are taken. In particular, this effect is remarkable in children, and Ba/G and Ba-containing composition liquids can also be used together with egg yolk lecithin as ingredients for improving the constitution for health drinks or health foods. It is. (Table 4) shows the clinical trial results. On the other hand, according to the published patent publication No. 1973-73509, which was mentioned in the beginning, powder and extract of yellow baicalin (estimated to be crude baicalin) can be used to treat rough skin, age spots, freckles, acne, and itching. It is reported to be effective. Therefore, we conducted a clinical trial on external application using the Ba/G or Ba-containing composition liquid obtained in the examples. I tried applying it three times, but I couldn't get the desired effect. On the other hand, when compared with known antihistamine-containing ointments, it is effective against itching as almost the same effect can be obtained. In addition, it has a fast-acting effect on areas affected by mosquito bites and eliminates itching. For eczema, it is effective for chronic eczema, but it could not be expected to be as fast-acting as the adrenal skin hormone-containing ointment. Furthermore, with regard to acne, the initial swelling accompanied by flushing was shown to have an anti-inflammatory tendency to disappear. However, overall, in order to enhance the above-mentioned effects, it is better to add a small amount of menthol when using it as an external preparation than to apply Ba/G or Ba-containing composition liquid alone. is better.

【表】 (表−2の注解) 表−2に示す成績結果は、前記実施例1におい
て特定された溶媒組成(混液:A〜C)の内、そ
のC(水とエタノールの割合が1:1の混液)中
に、Ba・G又はBaを0.6%添加し、前記実施例1
で特定した、可溶化安定剤(F)の中から、その1種
類(ニコチン酸アミド)を、Ba・GはBaの添加
量と同量、添加した時の溶液の安定性について、
各温度(60〜80℃、45℃恒温槽内、室温放置、5
〜10℃冷蔵庫内、−20℃冷凍庫内)を設定して、
1時間後〜12カ月後にわたる経時的変化(澱など
の沈殿物の発生の有無)について求めたものであ
る。 尚、前記実施例1で特定した、可溶化安定剤の
内、少なくともプロリン1種類からなるアミノ酸
類(D)と共に、更に少なくともサツカロース1種類
からなる糖類(E)、あるいは、前記実施例1で特定
した可溶化安定剤(F)の中から、その1種類(チオ
クト酸アミド、グルクロン酸アミド、尿素)を、
それぞれにおいて、上記と同様な方法で、Ba・
G又はBa含有組成液の安定性を求めてみたが、
そのいずれもが、ほぼ同等にして良好な成績結果
が得られた。 更に、用いた溶媒についても、混液A(水:ブ
ロピレングリコール=1:1)及び、混液B
(水:ブチレングリコール=1:1)の双方によ
り、上記のような可溶化安定剤の種々の組み合わ
せを試み、その安定剤を求めていたが、その結果
は、やはり同様にして、良好な安定性が保持され
ることがわかつた。
[Table] (Commentary to Table 2) The results shown in Table 2 are based on the solvent compositions (mixed liquids: A to C) specified in Example 1, and C (the ratio of water and ethanol is 1: 1), 0.6% of Ba・G or Ba was added to the mixture of Example 1.
Regarding the stability of the solution when one of the solubilization stabilizers (F) identified in (Nicotinic acid amide) was added in the same amount as Ba and G,
Various temperatures (60-80℃, 45℃ thermostat, left at room temperature, 5
~10℃ in the refrigerator, -20℃ in the freezer),
Changes over time (presence or absence of precipitates such as lees) were determined over a period of 1 hour to 12 months. In addition, among the solubilization stabilizers specified in Example 1, amino acids (D) consisting of at least one type of proline, and saccharides (E) consisting of at least one type of sutucarose, or One of the solubilization stabilizers (F) (thioctic acid amide, glucuronic acid amide, urea) was
In each case, Ba・
I tried to find the stability of the composition liquid containing G or Ba, but
In both cases, almost the same good results were obtained. Furthermore, regarding the solvents used, mixture A (water: propylene glycol = 1:1) and mixture B
(Water: butylene glycol = 1:1) We tried various combinations of solubilizing stabilizers such as those mentioned above, and searched for such stabilizers, but the results were similar. It was found that the gender was preserved.

【表】【table】

【表】 (表−3の注解) 表−3に示す成績結果は、Ba・G又はBa含有
組成液、ここでは、混液(A)〜(C)の内、(C)の溶媒
に、Ba・G又はBaを0.6%添加したものに、 更に、可溶化安定剤として、 何も添加しない場合(無添加) (D)で示すアミノ酸の中から、プロリンのみ
を、種々の割合で添加した場合 (E)で示す糖類の中から、サツカロースのみ
を、種々の割合で添加した場合 (F)で示す酸アミド化合物中の1種類のみ、又
は、尿素のみを種々の割合で添加した場合 プロリンと、サツカロースをそれぞれ、同量
づつ添加した場合、 プロリン、サツカロース及び、(F)で示す酸ア
ミド化合物の中から選択した、ニコチン酸アミ
ドを同量づつ添加した場合 の、〜の処方を用いて、調製した組成液につ
いて、2週間後の経時的変化を求めたときのもの
である。 尚、(A)及び(B)の溶媒についても、上記と同様の
試験をそれぞれ行つてみたが、いずれにしてもほ
ぼ同様にして、良好な結果が得られた。
[Table] (Commentary to Table 3) The results shown in Table 3 are based on the results shown in Table 3.・When 0.6% G or Ba is added, and in addition, nothing is added as a solubilization stabilizer (no addition) When only proline is added from among the amino acids shown in (D) in various proportions When only sutucarose is added in various proportions from among the sugars shown in (E) When only one type of acid amide compound shown in (F) or only urea is added in various proportions Proline and When the same amount of sutucarose is added, and when the same amount of nicotinic acid amide selected from among proline, sutucarose, and the acid amide compound shown in (F) is added, using the recipe of ~. This figure shows changes over time of the composition solution obtained after two weeks. Incidentally, tests similar to those described above were also conducted for the solvents (A) and (B), and good results were obtained in almost the same manner in either case.

【表】【table】

Claims (1)

【特許請求の範囲】[Claims] 1 水とプロピレングリコール又は水とブチレン
グリコール、又は水とエタノールの割合が1:1
の混液中に、主薬物としてバイカリン又はバイカ
レインを0.1〜0.6%含有し、可溶化安定剤とし
て、アミノ酸類の中から、少なくともプロリン1
種類と、糖類の中から、少なくともサツカロース
1種類を、それぞれ0.1〜1.2%を含有するか、又
は、可溶化安定剤として、ニコチン酸アミド、チ
オクト酸アミド、グルクロン酸アミド、尿素の
内、そのいずれか1種類を、0.1〜1.2%含有する
ことからなる、可溶化され、安定化されたことを
特徴とする化粧料用組成液。
1 The ratio of water and propylene glycol, water and butylene glycol, or water and ethanol is 1:1.
The mixture contains 0.1 to 0.6% of baicalin or baicalein as the main drug, and at least 1 proline from amino acids as a solubilization stabilizer.
Contains at least one type of sucarose from saccharides, 0.1 to 1.2% each, or contains nicotinamide, thioctic acid amide, glucuronic acid amide, or urea as a solubilizing stabilizer. 1. A cosmetic composition liquid characterized by being solubilized and stabilized and containing 0.1 to 1.2% of one of the following.
JP59173537A 1984-08-20 1984-08-20 Liquid composition containing baicalin or baicalein and external drug for skin or skin cosmetic containing same Granted JPS6150918A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59173537A JPS6150918A (en) 1984-08-20 1984-08-20 Liquid composition containing baicalin or baicalein and external drug for skin or skin cosmetic containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59173537A JPS6150918A (en) 1984-08-20 1984-08-20 Liquid composition containing baicalin or baicalein and external drug for skin or skin cosmetic containing same

Publications (2)

Publication Number Publication Date
JPS6150918A JPS6150918A (en) 1986-03-13
JPH0258245B2 true JPH0258245B2 (en) 1990-12-07

Family

ID=15962367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59173537A Granted JPS6150918A (en) 1984-08-20 1984-08-20 Liquid composition containing baicalin or baicalein and external drug for skin or skin cosmetic containing same

Country Status (1)

Country Link
JP (1) JPS6150918A (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61161219A (en) * 1985-01-08 1986-07-21 Osaka Chem Lab Skin composition for atopic dermatitis
JPS6383017A (en) * 1986-09-25 1988-04-13 Ichimaru Pharcos Co Ltd Anti-suntan cosmetic
JPS63253013A (en) * 1987-04-08 1988-10-20 Ichimaru Pharcos Co Ltd Melanization inhibitor
FR2628317B1 (en) * 1988-03-09 1991-11-08 Lvmh Rech COMPOSITION BASED ON HYDRATED LIPID LAMID PHASES OR LIPOSOMES CONTAINING SCUTELLARIA EXTRACT, OR AT LEAST ONE FLAVONOID SUCH AS BAICALINE OR BAICALINE AND COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, ANTI-ALLERGIC ANTI-ALLERGIC ACTIVITY THE INCORPORANT
JPH0610118B2 (en) * 1989-06-02 1994-02-09 東海コンクリート工業株式会社 Method for manufacturing glazed cement products
KR20020046400A (en) * 2000-12-14 2002-06-21 성재갑 Disposable diaper comprising skin protecting agent
KR100753760B1 (en) * 2000-12-21 2007-08-31 주식회사 엘지생활건강 Disposable absorptive product for prevention of rash
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
DE102009037900A1 (en) 2009-08-19 2010-06-02 Henkel Ag & Co. Kgaa Cosmetic or dermatological topical composition, useful e.g. for indicating intrinsic and extrinsic skin aging, comprises baicalin and an active substance e.g. 7-methoxy-2,2-dimethyl-chroman-6-ol or 7-methoxy-2,2-dimethyl-2H-chromen-6-ol
US9072919B2 (en) * 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9107853B2 (en) * 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
KR102261301B1 (en) * 2012-10-12 2021-06-07 로레알 Cosmetic compositions containing at least one hydrotrope and at least one active compound
US9669242B2 (en) * 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
CN103720650A (en) * 2014-01-17 2014-04-16 中国药科大学 Baicalin injection with anti-influenza virus effect
CN105732753B (en) * 2016-02-01 2018-03-06 承德医学院 A kind of purposes of the scutelloside magnesium compound and preparation method thereof with it
FR3060356B1 (en) * 2016-12-21 2020-01-17 L'oreal COMPOSITION COMPRISING BAICALIN AND / OR A DERIVATIVE THEREOF AND A NON-IONIC ASSOCIATIVE POLYURETHANE

Also Published As

Publication number Publication date
JPS6150918A (en) 1986-03-13

Similar Documents

Publication Publication Date Title
JPH0258245B2 (en)
CN100534530C (en) Vehicle for topical delivery of anti-inflammatory compounds
JP6337071B2 (en) Skin preparation for external use
WO1992010178A1 (en) Antipruritic drug and antipruritic composition
JP3487633B2 (en) Skin disease treatment emulsion
JP3665360B2 (en) Active oxygen scavenger and composition containing the same
JPS6245527A (en) Preventive and remedy for gray hair
EP1917075A1 (en) Composition in the form of a lipogel for cosmetic, cleansing and pharmaceutical use
JP5307309B2 (en) External preparation containing prednisolone valerate acetate and basic local anesthetic
JPH0217115A (en) Skin-beautifying cosmetic
JPS6360910A (en) Skin drug for external use
US20080317873A1 (en) Pain Relief Compositions
JPH03503177A (en) Compositions containing thymopentin for the topical treatment of diseases of the skin
WO1993024129A1 (en) Composition for treating acne vulgaris
JPS60244335A (en) Emulsified composition
JPS6322510A (en) External preparation for skin
JP2016130265A (en) Agent for inhibiting maillard reaction in living body or ages production inhibitor
JP3723728B2 (en) Skin topical solution
KR20080086229A (en) Cosmetic compositon containing azelaic acid for treating acne skin and its manufacturing method thereof
JPH10265365A (en) External preparation for skin for pimple
JPS6360909A (en) Skin drug for external use
JPS6322506A (en) External preparation for skin
JP3193028B2 (en) External preparation for treating atopic dermatitis containing nitroimidazole compound
KR0153203B1 (en) Cosmetic composition for moisturising and softening
JPH08283138A (en) Skin cosmetic

Legal Events

Date Code Title Description
S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313532

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313532

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term